Pharma BD Deal Intelligence
Novo Nordisk's $1.075B bet on CB1 inverse agonist monlunabant delivered promising Phase 2a data—7.1 kg weight loss at the 10mg dose versus 0.7 kg placebo—but the drug carries the same neuropsychiatric baggage (anxiety, irritability, sleep disturbance) that killed the entire CB1-blocker class before it. Too early to call, with a larger Phase 2b needed to settle the safety question.
Novo Nordisk acquired Inversago Pharma for $1B for obesity drug development.
Novo Nordisk to acquire obesity drug maker Inversago Pharma for up to $1 billion to expand weight loss portfolio beyond GLP-1
Novo acquires Inversago for up to $1 billion, spotlighting troubled weight loss approach with peripheral CB1 inverse agonist
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Novo Nordisk acquired Montreal-based Inversago Pharma (announced 10 Aug 2023, completed September 2023) for up to USD 1.075 billion in cash — an approximately USD 600 million upfront asset-acquisition purchase price plus up to ~USD 475 million in contingent development and commercial milestones. The deal brought in Inversago's lead asset INV-202, since renamed monlunabant, an oral peripherally-acting CB1 receptor inverse agonist, extending Novo's obesity and metabolic-disease pipeline beyond its GLP-1 franchise. In a Phase 2a obesity trial (243 patients, 16 weeks; reported 20 Sep 2024) all doses achieved statistically significant weight loss, with the 10 mg dose producing a 7.1 kg reduction versus 0.7 kg on placebo; gastrointestinal adverse events and dose-dependent mild-to-moderate neuropsychiatric effects (anxiety, irritability, sleep disturbance) were observed, echoing the historic liability of the CB1-blocker class. Novo planned a larger Phase 2b obesity study to begin in 2025.
42M US cases/yr · $50.0B US Obesity Therapeutics Market (2024E)
Obesity affects over 42% of US adults and is a major driver of type 2 diabetes, cardiovascular disease, and metabolic complications. Novo Nordisk acquired Inversago Pharma for its lead asset INV-202 (monlunabant), an oral peripheral CB1 inverse agonist designed to block cannabinoid receptor 1 in peripheral tissues without CNS effects, addressing the safety issues that doomed earlier CB1 blockers like rimonabant.
The obesity market is dominated by GLP-1 receptor agonists: Wegovy (semaglutide, Novo Nordisk) and Zepbound (tirzepatide, Lilly). Monlunabant offers a complementary oral mechanism targeting peripheral CB1 to improve metabolic parameters. Earlier CB1 blockers (rimonabant/Acomplia) were withdrawn due to psychiatric side effects from CNS penetration. Inversago approach focuses on peripheral selectivity.
Novo Nordisk completed $1B acquisition of Inversago Pharma, gaining INV-202, peripherally-acting CB1 receptor blocker for obesity.
INV-202 offers differentiated CB1 mechanism without CNS side effects of rimonabant class. Early development. Complements Novo's GLP-1 portfolio.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novo Nordisk A/S / Inversago Pharma (this deal) | 2023 | $1.1B | 61 |
| Novo Nordisk A/S / Emisphere Technologies | 2020 | $1.4B | 90 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2019 | $3.3B | 88 |
| Novo Nordisk A/S / Vivtex Inc. | 2026 | $2.1B | 69 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2021 | $3.3B | 68 |
| Novo Nordisk A/S / Forma Therapeutics Holdings Inc. | 2022 | $1.1B | 68 |
| Novo Nordisk A/S / Forma Therapeutics Holdings Inc. | 2022 | $1.1B | 58 |
← Browse all deals · How we score deals
More: 2023 deals · Novo Nordisk A/S deals · Metabolic deals